EWA
PTCT icon

EverSource Wealth Advisors’s PTC Therapeutics PTCT Stock Holding History

EverSource Wealth Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.2K Sell
885
-160
-15% -$11.6K ﹤0.01% 1554
2026
Q1 		$71.2K Buy
1,045
+151
+17% +$10.7K ﹤0.01% 1644
2025
Q4 		$67.9K Buy
894
+47
+6% +$3.42K ﹤0.01% 1536
2025
Q3 		$52K Sell
847
-296
-26% -$15.4K ﹤0.01% 1679
2025
Q2 		$55.8K Buy
1,143
+814
+247% +$38.6K ﹤0.01% 1545
2025
Q1 		$16.8K Buy
329
+221
+205% +$11K ﹤0.01% 1797
2024
Q4 		$4.87K Buy
108
+37
+52% +$1.58K ﹤0.01% 2363
2024
Q3 		$2.63K Buy
71
+10
+16% +$335 ﹤0.01% 2448
2024
Q2 		$2.06K Buy
61
+2
+3% +$65 ﹤0.01% 2539
2024
Q1 		$1.9K Buy
+59
New +$1.65K ﹤0.01% 2406
2023
Q2 		– Sell
-29
Closed -$1.41K – 2582
2023
Q1 		$1.41K Buy
+29
New +$1.33K ﹤0.01% 2037

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

EverSource Wealth Advisors's PTCT Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its PTC Therapeutics (PTCT) stake by 15% in Q2 2026, selling an estimated $11.6K and leaving 885 shares worth $72.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1554.

EverSource Wealth Advisors first reported a position in PTCT in Q1 2023 and has held it in 11 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • EverSource Wealth Advisors held 885 shares of PTC Therapeutics worth $72.2K as of Q2 2026.
  • EverSource Wealth Advisors sold 160 PTC Therapeutics shares in Q2 2026, an estimated $11.6K.
  • PTC Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1554 holding.
  • EverSource Wealth Advisors first reported a position in PTC Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.